{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    14,
    105
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "5",
        "name": "Amendment 5",
        "scope": {
          "id": "e1a6da83-88a1-4423-9ac5-d01a9bd6455b",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "bdf92ce2-4b8c-4304-9088-8c90669d99c7",
          "code": {
            "id": "75ed59e5-9e49-47ec-bbae-58a13f747b8b",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "05e83c87-8381-41a8-96f8-bb8c26581c28",
            "type": {
              "id": "c95685c6-396a-4c18-8c28-aa3dde50c432",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary purpose of this amendment is to provide study visit scheduling flexibility by allowing optional phone visits to be done at week -4, week 2 and for the Continuous Glucose Monitoring visits (weeks 10/11 and weeks 22/23) during the 24 week double blinded short term treatment period.",
        "effectiveDate": "2016-05-18",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2",
          "ar_1_3",
          "ar_1_4"
        ],
        "previousVersion": "Revised Protocol 01",
        "newVersion": "Revised Protocol 02"
      },
      {
        "id": "amend_2",
        "number": "3",
        "name": "Amendment 3",
        "scope": {
          "id": "1b082a3d-18b9-4077-8989-2c173c41ebdf",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "50e23b98-5aa5-4d95-a051-a59bff873f62",
          "code": {
            "id": "5158f1dc-541f-478d-a716-792359ba2c10",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "beae3cf6-5d3c-42eb-aabf-2791b6f0dfa5",
            "type": {
              "id": "5753d30b-ea56-4e02-bfbf-422fefb806dd",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary purpose of the amendment was to modify the Inclusion and Exclusion Criteria based on feedback from the European Medicines Agency (EMA). Specifically, the EMA has endorsed removing the requirement that HbA1c may not drop more than 0.5% during the lead-in phase.",
        "effectiveDate": "2015-05-06",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2",
          "ar_2_3"
        ],
        "previousVersion": "Original Protocol",
        "newVersion": "Revised Protocol 01"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_3",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_4",
        "code": "STATISTICAL",
        "description": "Statistical",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_3",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "Sweden",
        "instanceType": "Country",
        "code": "SE"
      },
      {
        "id": "country_2",
        "name": "Belgium",
        "instanceType": "Country",
        "code": "BE"
      },
      {
        "id": "country_3",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      }
    ],
    "studySites": [
      {
        "id": "site_1",
        "name": "Bristol-Myers Squibb Research and Development",
        "instanceType": "StudySite",
        "countryId": "country_2",
        "city": "Braine-l’Alleud"
      },
      {
        "id": "site_2",
        "name": "Bristol-Myers Squibb Research and Development",
        "instanceType": "StudySite",
        "countryId": "country_3",
        "city": "Lawrenceville"
      }
    ],
    "summary": {
      "amendmentCount": 2,
      "countryCount": 3,
      "siteCount": 2
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1",
        "country_2",
        "country_3"
      ],
      "regions": [
        "Europe",
        "North America"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "5",
        "effectiveDate": "2016-05-18",
        "summary": "The primary purpose of this amendment is to provide study visit scheduling flexibility by allowing optional phone visits to be done at week -4, week 2 and for the Continuous Glucose Monitoring visits (weeks 10/11 and weeks 22/23) during the 24 week double blinded short term treatment period.",
        "previousVersion": "Revised Protocol 01",
        "newVersion": "Revised Protocol 02",
        "reasons": [
          "Operational",
          "Scientific",
          "Safety",
          "Statistical"
        ]
      },
      {
        "number": "3",
        "effectiveDate": "2015-05-06",
        "summary": "The primary purpose of the amendment was to modify the Inclusion and Exclusion Criteria based on feedback from the European Medicines Agency (EMA). Specifically, the EMA has endorsed removing the requirement that HbA1c may not drop more than 0.5% during the lead-in phase.",
        "previousVersion": "Original Protocol",
        "newVersion": "Revised Protocol 01",
        "reasons": [
          "Regulatory",
          "Scientific",
          "Operational"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [
        {
          "name": "Sweden",
          "code": "SE"
        },
        {
          "name": "Belgium",
          "code": "BE"
        },
        {
          "name": "United States",
          "code": "US"
        }
      ],
      "regions": [
        "Europe",
        "North America"
      ],
      "plannedSites": null
    },
    "sites": [
      {
        "name": "Bristol-Myers Squibb Research and Development",
        "city": "Braine-l’Alleud",
        "country": "Belgium"
      },
      {
        "name": "Bristol-Myers Squibb Research and Development",
        "city": "Lawrenceville",
        "country": "United States"
      }
    ]
  }
}